HER3 protein expression as a risk factor for post‑operative recurrence in patients with early‑stage adenocarcinoma and adenosquamous carcinoma of the cervix
Takaaki Mizuno, Kenji Tamura(Unknown)
Cited by 10
Related Papers
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2021|412
Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study
|Cancer Science|2019|375
First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors
|Clinical Cancer Research|2021|97
Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer
|Oncology Letters|2020|21